Kezar Life Sciences to be acquired by Aurinia Pharma for $6.955 per share cash plus CVR

Kezar Life Sciences, Inc.

Aurinia Pharma U.S. will commence a tender offer at $6.955/share cash plus one contingent value right (CVR) per share.
Tang Capital Partners, holding ~9% of shares, agrees to tender in support of the deal.
CVR holders may receive payments from excess net cash above $50M, Enodia APA proceeds, and milestones/royalties from zetomipzomib.
Closing expected in Q2 2026; conditions include minimum tender >50% and net cash ≥$50M.
Termination fee of $1.2 million payable by Kezar under specified circumstances, including a superior proposal.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Kezar Life Sciences, Inc. entered into Agreement and Plan of Merger with Aurinia Pharma U.S., Inc. valued at $6.955 per Share (effective 2026-03-30).

Action: entry
Agreement: merger
Counterparty: Aurinia Pharma U.S., Inc.
Value: $6.955 per Share
Effective: 2026-03-30

Exact text from the filing

On March 30, 2026, Kezar Life Sciences, Inc., a Delaware corporation (the “ Company ” or “ Kezar ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Aurinia Pharma U.S., Inc., a Delaware corporation (“ Parent ” or “Aurinia”), Aurinia Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ” and together with Parent, the “ Buyer Entities ”), and, solely for purposes of Section 10.13 of the Merger Agreement, Aurinia Pharmaceuticals Inc., a company incorporated under the laws of the Province of Alberta (“ Ultimate Parent ”), and the parent entity of Parent.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-130486

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.